Kim, Yong-Ku and Na, Kyoung-Sae 2018. Application of machine learning classification for structural brain MRI in mood disorders: Critical review from a clinical perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 80, p. 71.
dos Santos, Éverton Renan Q. Maia, Cristiane Socorro F. Fontes Junior, Enéas A. Melo, Ademar S. Pinheiro, Bruno G. and Maia, José Guilherme S. 2018. Linalool-rich essential oils from the Amazon display antidepressant-type effect in rodents. Journal of Ethnopharmacology, Vol. 212, p. 43.
Park, Seon-Cheol Lee, Min-Soo Hahn, Sang Woo Kanba, Shigenobu Chong, Mian-Yoon Chee, Kok Yoon Udomratn, Pichet Tripathi, Adarsh Sartorius, Norman Shinfuku, Naotaka Tanra, Andi J and Park, Yong Chon 2017. Clinical Characteristics and Psychotropic Prescribing Patterns Associated with impaired Concentration in Asians with Depressive Disorders: The REAP-AD Study. The Tohoku Journal of Experimental Medicine, Vol. 242, Issue. 2, p. 151.
.Gillan, Claire M and Whelan, Robert 2017. What big data can do for treatment in psychiatry. Current Opinion in Behavioral Sciences, Vol. 18, p. 34.
Szczepanik, Joanna E. Furey, Maura L. Nugent, Allison C. Henter, Ioline D. Zarate, Carlos A. and Lejuez, Carl W. 2017. Altered interaction with environmental reinforcers in major depressive disorder: Relationship to anhedonia. Behaviour Research and Therapy, Vol. 97, p. 170.
Oluboka, Oloruntoba J Katzman, Martin A Habert, Jeffrey McIntosh, Diane MacQueen, Glenda M Milev, Roumen V McIntyre, Roger S and Blier, Pierre 2017. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology,
Gao, Keming Sweet, Jennifer Su, Meilei and Calabrese, Joseph R. 2017. Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample. Asian Journal of Psychiatry, Vol. 27, p. 40.
Wagner, Stefanie Tadić, André Roll, Sibylle C. Engel, Alice Dreimüller, Nadine Engelmann, Jan and Lieb, Klaus 2017. A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depressive Disorders. Journal of Affective Disorders, Vol. 221, p. 184.
Webb, Christian A. Olson, Elizabeth A. Killgore, William D.S. Pizzagalli, Diego A. Rauch, Scott L. and Rosso, Isabelle M. 2017. Rostral Anterior Cingulate Cortex Morphology Predicts Treatment Response to Internet-Based Cognitive Behavioral Therapy for Depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging,
Groeneweg-Koolhoven, Isis Ploeg, Merel Comijs, Hannie C. WJH Penninx, Brenda van der Mast, Roos C. Schoevers, Robert A. Rhebergen, Didi and Exel, Eric van 2017. Apathy in early and late-life depression. Journal of Affective Disorders, Vol. 223, p. 76.
Martynhak, Bruno Jacson Hogben, Alexandra L. Zanos, Panos Georgiou, Polymnia Andreatini, Roberto Kitchen, Ian Archer, Simon N. von Schantz, Malcolm Bailey, Alexis and van der Veen, Daan R. 2017. Transient anhedonia phenotype and altered circadian timing of behaviour during night-time dim light exposure in Per3−/− mice, but not wildtype mice. Scientific Reports, Vol. 7, p. 40399.
Fettes, Peter Schulze, Laura and Downar, Jonathan 2017. Cortico-Striatal-Thalamic Loop Circuits of the Orbitofrontal Cortex: Promising Therapeutic Targets in Psychiatric Illness. Frontiers in Systems Neuroscience, Vol. 11,
Blier, Pierre Gommoll, Carl Chen, Changzheng and Kramer, Kenneth 2017. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. Journal of Affective Disorders, Vol. 210, p. 273.
Vinckier, F. Gourion, D. and Mouchabac, S. 2017. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. European Psychiatry, Vol. 44, p. 1.
Liu, Wen-Hua Valton, Vincent Wang, Ling-Zhi Zhu, Yu-Hua and Roiser, Jonathan P. 2017. Association between habenula dysfunction and motivational symptoms in unmedicated major depressive disorder. Social Cognitive and Affective Neuroscience, Vol. 12, Issue. 9, p. 1520.
Escalona, Rodrigo and Fawcett, Jan 2017. Pramipexole in Treatment Resistant-Depression, Possible Role of Inflammatory Cytokines. Neuropsychopharmacology, Vol. 42, Issue. 1, p. 363.
Lawson, R P Nord, C L Seymour, B Thomas, D L Dayan, P Pilling, S and Roiser, J P 2017. Disrupted habenula function in major depression. Molecular Psychiatry, Vol. 22, Issue. 2, p. 202.
Wagner, Stefanie Engel, Alice Engelmann, Jan Herzog, David Dreimüller, Nadine Müller, Marianne B. Tadić, André and Lieb, Klaus 2017. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. Journal of Psychiatric Research, Vol. 94, p. 96.
Hayes, Brett 2017. The Category Use Effect in Clinical Diagnosis. Clinical Psychological Science, p. 216770261771252.
Olbert, Charles M. Rasmussen, Andrew Gala, Gary J. and Tupler, Larry A. 2016. Treatment outcome variation between depression symptom combinations in the STAR*D study. Journal of Affective Disorders, Vol. 201, p. 1.
Symptom dimensions have not yet been comprehensively tested as predictors of the substantial heterogeneity in outcomes of antidepressant treatment in major depressive disorder.
We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP). The effects of symptom dimensions were tested in mixed-effect regression models that controlled for overall initial depression severity, age, sex and recruitment centre. Significant results were tested for replicability in 3637 adult out-patients with non-psychotic major depression treated with citalopram in level I of Sequenced Treatment Alternatives to Relieve Depression (STAR*D).
The interest-activity symptom dimension (reflecting low interest, reduced activity, indecisiveness and lack of enjoyment) at baseline strongly predicted poor treatment outcome in GENDEP, irrespective of overall depression severity, antidepressant type and outcome measure used. The prediction of poor treatment outcome by the interest-activity dimension was robustly replicated in STAR*D, independent of a comprehensive list of baseline covariates.
Loss of interest, diminished activity and inability to make decisions predict poor outcome of antidepressant treatment even after adjustment for overall depression severity and other clinical covariates. The prominence of such symptoms may require additional treatment strategies and should be accounted for in future investigations of antidepressant response.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between September 2016 - 17th November 2017. This data will be updated every 24 hours.